McKesson's strategic growth in oncology, biopharma and tech drives momentum in 2025. Will MCK overcome its sustaining challenges with robust finances and innovation?

McKesson's stock appears undervalued, trading at 18 times forward earnings and free cash flow. See why MCK is a Hold.

The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...

McKesson (NYSE:MCK – Get Free Report) had its price objective cut by Citigroup from $713.00 to $677.00 in a research note ...

McKesson has launched McKesson Amplify, a strategic initiative intended to help protect critical pharmacy services and elevate the pharmacy profession by strengthening the voice of the ...

AdvisorNet Financial Inc lessened its holdings in McKesson Co. (NYSE:MCK – Free Report) by 11.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional ...

Beyond funding, McKesson Amplify also will provide resources, strategic support and other tools to help state pharmacy associations achieve their local and state advocacy goals in 2025.

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers ...

Guided by McKesson's core belief that the patient comes first, McKesson Amplify is a strategic initiative intended to help protect critical pharmacy services and elevate the pharmacy profession by ...